Esophageal Squamous Cell Carcinoma
Conditions
Interventions
experimental group:Tislelizumab Injection
Sponsors
Qilu Hospital of Shandong University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-75 years, no gender limitation; 2. The ECOG score of the patient is 0 or 1; 3. Patients who have not received previous anti-tumor therapy (surgery, radiotherapy, chemotherapy, immunotherapy); 4. Histopathological diagnosis of locally advanced esophageal squamous cell carcinoma was II-IVa; 5. Clinical evaluation of patients with infeasible radical resection of esophageal cancer or rejection of surgery; 6. Plan to receive tirelizumab and radical radiotherapy and chemotherapy; 7. The expected treatment period of tirelizumab >=2; 8. Sign informed consent.
Exclusion criteria
Exclusion criteria: 1. The patient had contraindications of immunotherapy and radical radiotherapy and chemotherapy; 2. Patients with high-risk esophageal perforation; 3. Patients planned to receive surgical treatment such as esophagectomy; 4. Patients with distant metastasis cannot be excluded clinically.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-year overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| objective response rate (ORR);progression-free survival (PFS);treatment-related adverse events (TRAE);immune-related adverse events (irAE); | — |
Countries
China
Contacts
Public ContactCheng Yufeng
Qilu Hospital of Shandong University
Outcome results
None listed